Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multiple-dose, Parallel Group Study to Evaluate the Pharmacokinetics of MK-6916 in Participants With Severe Renal Impairment and Moderate Renal Impairment

NCT07922174 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07922174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multiple-dose, Parallel Group Study to Evaluate the Pharmacokinetics of MK-6916 in Participants With Severe Renal Impairment and Moderate Renal Impairment
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 11, 2026
Completion date
August 8, 2027
Enrollment
32 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, renal impairment

Arms

As registered; 3 arms.

  • Panel A: Severe Renal Impairment ExperimentalMK-6916

    Participants with severe renal impairment will receive multiple doses of MK-6916 on Days 1-15 and a single oral dose on Day 16 under fasting conditions.

  • Panel B: Moderate Renal Impairment ExperimentalMK-6916

    Participants with moderate renal impairment will receive multiple doses of MK-6916 on Days 1-15 and a single oral dose on Day 16 under fasting conditions.

  • Panel C: Healthy ExperimentalMK-6916

    Healthy participants will receive multiple doses of MK-6916 on Days 1-15 and a single oral dose on Day 16 under fasting conditions.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Area Under the Concentration-Time Curve from Time 0 to 12 Hours (AUC0-12) of MK-6916 on Day 16 Day 16: Predose and at designated timepoints (up to approximately 12 hours postdose)

    Blood samples will be collected to determine the AUC0-12 of MK-6916.

Lead sponsor's other trials

Merck Sharp & Dohme LLC, most recent start first.

Similar trials

Same condition (Renal Insufficiency) and phase, most recent start first.